You are here

Somatuline Depot Approved to Treat Carcinoid Syndrome

Injection is also approved for GEP-NETs

Lanreotide injection (Somatuline Depot, Ipsen Biopharmaceuticals, Inc.) 120 mg has received FDA approval for a new indication: the treatment of carcinoid syndrome. When used, it reduces the frequency of short-acting somatostatin analog rescue therapy.

The medication, a somatostatin analog, is also approved for the improvement of progression-free survival in patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The additional approval for carcinoid syndrome was based on “Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (ELECT): A Randomized, Double-Blind, Placebo-Controlled Trial,” published in Endocrine Practice.

In this 16-week, randomized, double-blind, phase 3 trial, patients with and without prior somatostatin analog use were randomized to lanreotide depot/autogel 120 mg or placebo every four weeks, with access to short-acting octreotide as rescue medication. The primary endpoint was the percentage of days in which short-acting octreotide was used, which was assessed by an analysis of daily diaries.

A total of 115 patients were enrolled (lanreotide, n = 59; placebo, n = 56). The adjusted mean percentage of days with rescue octreotide use was significantly lower in the lanreotide group (33.7%; 95% confidence interval [CI], 25.0%–42.4%) versus the placebo group (48.5%; 95% CI, 39.6%–57.4%). The odds ratio (OR) of full/partial treatment success (three days or less of short-acting octreotide use in weeks 12 to 15) was significantly greater with lanreotide than placebo (OR, 2.4; 95% CI, 1.1–5.3; P = .036).

Sources: Ipsen; September 18, 2017; Endocrine Practice; September 2016.

More Headlines

Manufacturer used FDA’s 505(b)(2) abbreviated approval pathway
This is the first drug for patients with eosinophilic granulomatosis with polyangiitis
Industry will provide funding for programs in partnership with Addiction Policy Forum
Platform offers advanced technology to treat symptoms of Parkinson’s disease
Four in 10 remain in complete remission, updated data show
Patients with high PD-L1 level show benefit in first-line treatment
Pfizer launches generic to counteract Teva’s version
Tecentriq was combined with Avastin and chemotherapy as initial treatment